Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies

Annals of Clinical and Translational Neurology

Volumn 3, Issue 10, 2016, Pages 812-818

  Fairfoul, Graham ^a   McGuire, Lynne I ^a   Pal, Suvankar ^a,b   Ironside, James W ^a   Neumann, Juliane ^c   Christie, Sharon ^c   Joachim, Catherine ^c   Esiri, Margaret ^c   Evetts, Samuel G ^c   Rolinski, Michal ^c   Baig, Fahd ^c   Ruffmann, Claudio ^c   Wade Martins, Richard ^c   Hu, Michele T M ^c   Parkkinen, Laura ^c   Green, Alison J E ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN;

ALPHA SYNUCLEINOPATHY; ALZHEIMER DISEASE; ARTICLE; BRAIN DEATH; BRAIN DEVELOPMENT; CEREBROSPINAL FLUID; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; DEMENTIA; HUMAN; HUMAN TISSUE; NEURODEGENERATIVE DISEASE; NEUROMODULATION; PARASOMNIA; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY;

EID: 85033548081     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.338     Document Type: Article

References (19)

1. Spillantini MG, Divane A, Goedert M. Assignment of human alpha-synuclein (SNCA) and beta-synuclein (SNCB) geners to chromosome 4q21 and 5q35. Genomics 1995;27:379–381.
2. Goedert M, Spillantini MG, Del Tredici K, et al. 100 years of lewy pathology. Nat Rev Neurol 2013;9:13–24.
3. Martf MJ, Tolsa E, Campdelacreu J. Clinical overview of the synucleinopathies. Mov Disord 2003;18:S21–S27.
4. Mollenhauer M, Cullen V, Kahn I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 2008;213:315–325.
5. Williams SM, Schult P, Sierks MR. Oligomeric a-synuclein an B-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases. Eur J Neurosci 2016;43(1):3–16.
6. Shi M, Bradner J, Hancock AM. Cerebrospinal fluid biomarkers for Parkinson's disease diagnosis and progression. Ann Neurol 2011;69:570–580.
7. Ohrfelt A, Grognet P, Andreasen N, et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders- a marker of synapse loss? Neurosci Lett 2009;450:332–335.
8. Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010;133:713–726.
9. Kruse N, Persson S, Alcolea D, et al. Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiol Aging 2015;36:2587–2596.
10. Bernis ME, Babila JT, Breid S, et al. Prion-lie propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein. Acta Neuropathol Commun 2015;3:1–18.
11. Brandel JP, Corbille AG, Derkinderen P, et al. Is Parkinson's disease a prion disease? Rev Neurol (Paris) 2015;171:812–824.
12. McGuire L, Peden A, Orru C, et al. Prion seeding activity in cerebrospinal fluid from patients with sporadic Creutzfeldt-Jakob disease patients using real-time QuIC analysis: a potential new clinical diagnostic test with high sensitivity and specificity. Ann Neurol 2012;72:278–285.
13. Clarke R, Smith AD, Jobst KA, et al. Folate, vitamin B12 and serum total homocysteine levels n confirmed Alzheimer's disease. Arch Neurol 1998;55:1449–1455.
14. Szewwczyk-Krolikowski K, Tomlinson P, Nithi K, et al. The influence of age and gender on motor and non-motor features of early Parkinson's disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. Parkinsonism Relat Disord 2014;20:99–105.
15. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease - a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.
16. Rolinski M, Zokaei N, Baig F, et al. Visual short-term memory deficits in REM sleep behaviour disorder mirror those in Parkinson's disease. Brain 2016;139:47–53.
17. Iranzo A, Tolosa E, Gelpi E, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet 2013;12:443–453.
18. Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathological assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012;123:1–11.
19. Kovacs GG, Alafuzoff I, AI-Sarraj S, et al. Mixed brain pathologies in dementia: the BrainNet Europe consortium experience. Dement Geriatr Cogn Disord 2008;26:343–350.